Pharmally

Pharmally
Name	Pharmally Pharmaceutical Corporation
Type	Private
Industry	Pharmaceuticals
Founded	2019
Founders	Yin Xiangjie; Huang Tzu Yen; Lin Tianrong
Headquarters	Manila, Philippines
Products	Medical supplies, pharmaceuticals

Pharmally

Pharmally is a Philippine pharmaceutical supplier that became prominent after securing high-value procurement contracts during the COVID-19 pandemic in the Philippines; the company attracted scrutiny from media outlets such as Philippine Daily Inquirer, Rappler, and ABS-CBN and was the subject of parliamentary oversight by the House of Representatives of the Philippines, the Senate of the Philippines, and executive commentary from the Office of the President of the Philippines. Its rapid contract awards intersected with procurement rules under the Bayanihan to Heal as One Act, connections to business figures linked to Department of Budget and Management (Philippines), and reporting by investigative journalists from The New York Times and Reuters.

Background and founding

The firm was established in 2019 in Manila by a group of entrepreneurs including individuals reported in press coverage such as Yin Xiangjie, Huang Tzu Yen, and Lin Tianrong, with early corporate registrations filed with the Securities and Exchange Commission (Philippines) and business addresses listed in Makati and Taguig. Foundational reporting traced lines to business networks involving traders with prior dealings in medical imports and to financial intermediaries connected to entities in China and Hong Kong, prompting attention from commentators writing for Philippine Star, Manila Bulletin, and Inquirer.net. Corporate formation documents were discussed alongside procurement timelines for pandemic response supplies under measures enacted by the Philippine Congress and directives from the Inter-Agency Task Force for the Management of Emerging Infectious Diseases (Philippines).

Business operations and products

Pharmally’s stated activities include the distribution and supply of medical goods such as surgical masks, personal protective equipment, and COVID-19 testing kits, which aligned with procurement categories specified by the Department of Health (Philippines), the Department of Budget and Management (Philippines), and hospital systems like the Philippine General Hospital. Commercial records and shipment manifests cited by reporters indicated import arrangements with manufacturers in China, freight coordination with logistics firms operating through the Port of Manila, and invoicing handled through banking institutions in Manila and Singapore. Product lines reportedly included disposable medical supplies, pharmaceuticals regulated by the Food and Drug Administration (Philippines), and commodities referenced in purchase orders from regional health offices and the Philippine Red Cross.

Role in Philippine government contracts and controversies

During the COVID-19 pandemic in the Philippines, Pharmally was awarded multiple procurement contracts by agencies including the Department of Budget and Management (Philippines) and the Department of Health (Philippines) under emergency procurement provisions of the Bayanihan to Heal as One Act. Contract values and timelines were highlighted in hearings convened by the Senate of the Philippines and the House of Representatives of the Philippines, and reporting by ABS-CBN News, GMA Network, and Rappler emphasized issues such as company capitalization, bid processes, and delivery performance. Controversies centered on allegations raised by lawmakers from blocs such as Senate Committee on Accountability and speakers in the House Committee on Good Government regarding due diligence, alleged links to personalities associated with the Office of the President of the Philippines, and comparisons to prior procurement matters investigated by the Commission on Audit (Philippines).

Investigations and legal proceedings

Parliamentary inquiries included televised hearings in the Senate of the Philippines chaired by senators such as Panfilo Lacson and Richard Gordon, which summoned company executives and government officials; law enforcement interest involved the Philippine National Police and the National Bureau of Investigation (Philippines) alongside probes by the Department of Justice (Philippines)]. Legal proceedings addressed questions about contract performance, alleged falsification of documents, and potential violations of procurement law under the Anti-Graft and Corrupt Practices Act (Republic Act No. 3019). International reporting by BBC News and The Washington Post chronicled subpoenas, executive depositions, and coordination with financial regulators in Singapore amid freezes and audits of bank accounts tied to corporate shareholders.

Political and public response

The affair elicited responses across the Philippine political spectrum, with critics including members of opposition coalitions in the House of Representatives of the Philippines and allies of former administrations, while supporters and spokespeople aligned with the Office of the President of the Philippines defended procurement decisions as emergency measures under the Bayanihan Acts. Civil society actors such as Transparency International Philippines and legal scholars from institutions like the University of the Philippines and Ateneo de Manila University issued statements about transparency and accountability, and mass media coverage in outlets like Philippine Daily Inquirer, Rappler, and GMA Network shaped public perception. Demonstrations and commentary from advocacy groups connected to anti-corruption campaigns and health sector stakeholders were reported around hearings at venues such as the Sandiganbayan and legislative buildings in Quezon City.

Impact and aftermath

The episode prompted reviews of emergency procurement rules overseen by the Commission on Audit (Philippines), legislative proposals in the House of Representatives of the Philippines and the Senate of the Philippines to tighten procurement standards, and administrative actions within the Department of Budget and Management (Philippines) and the Department of Health (Philippines). It influenced broader discussions in think tanks such as the Asia Foundation and policy institutes including the Philippine Institute for Development Studies on resilience of public procurement and pandemic preparedness. Judicial and administrative outcomes affected corporate registrants, spurred compliance reforms among suppliers active in health procurement, and fed into electoral messaging during campaigns involving figures from the 2022 Philippine presidential election and subsequent political cycles.

Category:Pharmaceutical companies of the Philippines